| pubmed-article:8199567 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0149615 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0018133 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0021031 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0008902 | lld:lifeskim |
| pubmed-article:8199567 | lifeskim:mentions | umls-concept:C0059994 | lld:lifeskim |
| pubmed-article:8199567 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8199567 | pubmed:dateCreated | 1994-7-7 | lld:pubmed |
| pubmed-article:8199567 | pubmed:abstractText | Ninety-one patients with de novo acute myeloid leukemia (AML) in first complete remission (CR) undergoing an HLA-identical sibling BMT and with a minimum follow-up of 12 months were analyzed for disease-related and transplant-related variables predicting survival and relapse. The overall actuarial 5 year survival is 53% and the relapse rate 29%, with a medium follow-up for surviving patients of 1552 days (range 365-4094 days). In univariate analysis the following variables were found to be associated with an increased risk of failure: high-dose cyclosporin (CsA), M4-M6 FAB subtype and a long interval (> or = 180 days) between diagnosis and BMT. Other disease-related variables at presentation were not significant, including WBC count > 50 x 10(9)/l, marrow blasts < 70%, time to enter remission > 40 days and > 2 courses to enter remission. Survival was 58% vs 43% for M1-M3 vs M4-M6 FAB subtypes (p = 0.03) and 71% vs 42% for low-dose vs high-dose CsA (p = 0.01). A multivariate analysis was then run separately on survival, relapse and transplant related mortality (TRM). Survival was negatively influenced by M4-M6 FAB subtypes (p = 0.009), high-dose CsA (p = 0.03) and a long interval between diagnosis and BMT (p = 0.04). Leukemia relapse was higher in patients receiving high-dose CsA (p = 0.003) and in females (p = 0.04). Transplant-related mortality was higher in FAB M4-M6 patients (p = 0.01) and patients grafted late after diagnosis (p = 0.03).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:8199567 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8199567 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8199567 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8199567 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8199567 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8199567 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8199567 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:BacigalupoAA | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:VitaliRR | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:Van LintM TMT | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:OcchiniDD | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:FrassoniFF | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:FagioliFF | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:LamparelliTT | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:GualandiFF | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:SognoGG | lld:pubmed |
| pubmed-article:8199567 | pubmed:author | pubmed-author:ClavioMM | lld:pubmed |
| pubmed-article:8199567 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8199567 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:8199567 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8199567 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8199567 | pubmed:pagination | 247-52 | lld:pubmed |
| pubmed-article:8199567 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:meshHeading | pubmed-meshheading:8199567-... | lld:pubmed |
| pubmed-article:8199567 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8199567 | pubmed:articleTitle | Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. | lld:pubmed |
| pubmed-article:8199567 | pubmed:affiliation | Divisione Ematologia 2, Ospedale San Martino, Genova, Italy. | lld:pubmed |
| pubmed-article:8199567 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8199567 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8199567 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8199567 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
